Revolution Medicines Inc
RVMDLatest QuantConomy context for RVMD: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Revolution Medicines Inc
QuantConomy has a structured record for RVMD. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- RVMD
- Name
- Revolution Medicines Inc
- Coverage
- 3 market/data records
- Sources
- alpaca fmp alphavantage sec nasdaq
Recent signals for RVMD
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| dry up | neutral | 26 | Jul 1, 02:08 PM | RVMD volume dry-up: 18% of expected volume for Wednesday 14:00 UTC, price flat 0.13% (strength 26) |
| dry up | neutral | 17 | Jun 30, 07:21 PM | RVMD volume dry-up: 22% of expected volume for Tuesday 19:00 UTC, price flat 0.01% (strength 17) |
| volume spike | neutral | 38 | Jun 30, 06:14 PM | RVMD volume spike: 273% of expected volume for Tuesday 18:00 UTC, price flat 0.04% (strength 38) |
PROPOSED_SALE signals are experimental: historical Form 144 coverage is still being backfilled, so results may be sparse or empty.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| RVMD | NASDAQ | alpaca | Revolution Medicines, Inc. Common Stock |
| RVMD | NASDAQ | fmp | Revolution Medicines, Inc. |
| RVMD | NASDAQ | alphavantage | Revolution Medicines Inc |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Patel Sushil | Director | exercise | 2,955 | $37.54 | $110,931 | 4 on EDGAR |
| Jun 24, 2026 | Anders Jack | Chief Financial Officer | exercise | 20,000 | $18.56 | $371,200 | 4 on EDGAR |
| Jun 18, 2026 | Patel Sushil | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 18, 2026 | Clyburn Frank | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 18, 2026 | Kim Lorence H. | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 18, 2026 | Borisy Alexis | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 18, 2026 | Horning Sandra | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 18, 2026 | ANDERSON ELIZABETH M | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 18, 2026 | Borellini Flavia | Director | grant | 1,191 | $0.00 | $0 | 4 on EDGAR |
| Jun 16, 2026 | Kelsey Stephen Michael | See Remarks | sale | 4,175 | $156.12 | $651,798 | 4 on EDGAR |
| Jun 16, 2026 | Mancini Anthony | See Remarks | sale | 4,615 | $156.12 | $720,490 | 4 on EDGAR |
| Jun 16, 2026 | Anders Jack | Chief Financial Officer | sale | 2,722 | $156.12 | $424,956 | 4 on EDGAR |
| Jun 16, 2026 | Cislini Jeff | General Counsel | sale | 2,157 | $156.12 | $336,749 | 4 on EDGAR |
| Jun 16, 2026 | GOLDSMITH MARK A | See Remarks | sale | 10,020 | $156.12 | $1,564,310 | 4 on EDGAR |
| Jun 11, 2026 | Horn Margaret A | Chief Operating Officer | exercise | 1,094 | $42.45 | $46,440 | 4 on EDGAR |
| May 26, 2026 | Mancini Anthony | See Remarks | exercise | 3,121 | $33.62 | $104,928 | 4 on EDGAR |
| Apr 27, 2026 | Mancini Anthony | See Remarks | exercise | 3,120 | $33.62 | $104,894 | 4 on EDGAR |
| Apr 15, 2026 | GOLDSMITH MARK A | See Remarks | exercise | 23,244 | $4.09 | $95,068 | 4 on EDGAR |
| Mar 25, 2026 | Mancini Anthony | See Remarks | exercise | 37,450 | $33.62 | $1,259,069 | 4 on EDGAR |
| — | Mancini Anthony | See Remarks | — | — | — | — | 3 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query RVMD context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access